Clinical trial • Phase I • Dermatology
KM-023 for Olmsted syndrome
Phase I trial of KM-023 for Olmsted syndrome. 64 participants.
Overview
- Trial Therapeutic Area
- Dermatology
- Trial Disease
- Olmsted syndrome
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 27-03-2025
- First CTIS Authorization Date
- 25-06-2025
Trial design
Phase I trial in France.
- Target Sample Size
- 64
Recruitment
- Planned Sample Size
- 64
- Recruitment Window Months
- 13
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 64
France
- Earliest CTIS Part Ii Submission Date
- 14-05-2025
- Latest Decision Or Authorization Date
- 02-04-2026
- Processing Time Days
- 323
- Number Of Sites
- 2
- Number Of Participants
- 64
Sites
- Site Name
- Biotrial
- Department Name
- Unité Clinique
- Contact Person Name
- Sophie Hays
- Contact Person Email
- sophie.hays@biotrial.com
- Site Name
- Hopital Necker Enfants Malades
- Department Name
- Service de dermatologie
- Contact Person Name
- Alain Hovnanian
- Contact Person Email
- alain.hovnanian@inserm.fr
Sponsor
Primary sponsor
- Full Name
- Kamari Pharma Ltd.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Israel
Investigational products
- Investigational Product Name
- KM-023
- First In Human
- Yes
Related trials
Other published trials that may interest you.